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A Vision- and Life-threatening Case of Peripheral Ulcerative Keratitis 
Abstract 
Background: Peripheral ulcerative keratitis (PUK) is a rare but severe ocular manifestation most 
commonly associated with rheumatoid arthritis amongst other autoimmune diseases. Quick diagnosis 
and co-management with corneal specialist and rheumatologist are crucial to preserve vision and life. A 
rare case of PUK associated with rheumatoid arthritis (RA) is presented with updates on current 
understanding and co-management of this condition. 
Case Report: A 76 year-old Caucasian male presented to the eye clinic on a Friday as a new patient, with a 
chief complaint of a red right eye started two weeks ago and was treated with erythromycin ointment, but 
it got worse with moderate pain so he was referred over from the urgent care clinic. His BCVA OD, OS was 
20/80 PHNI and PH20/25, respectively. Anterior segment evaluation showed severe conjunctival 
chemosis and injection, a superior temporal circular infiltrate and an inferior temporal linear infiltrate 
across the cornea with moderate corneal edema. Chart review confirmed the patient has been treated for 
rheumatoid arthritis with hydroxychloroquine and leflunomide for several years. The patient was 
diagnosed with PUK with mild scleritis associated with (RA) and initially treated with tobradex topical 
drops OD qid. His rheumatologist was contacted for co-management, and the patient was to return to 
clinic after the weekend. On the follow up visit, the patient felt better but the linear infiltrate persisted so 
oral prednisone 60mg/day was started with ofloxacin qid instead of Tobradex qid. The condition 
continued to improve over the next few follow up however the linear thinning of the cornea was not fully 
resolved so the patient was referred to a local corneal specialist. His rheumatologist continued to 
manage his RA closely and the patient confirmed that he was doing better overall at the latest visit. 
Conclusion: In cases of PUK with stromal thinning and scleritis, autoimmune diseases such as RA and 
systemic lupus erythema often are the underlying systemic cause. Prompt diagnosis and co-management 
with other specialists are essential to minimize irreversible vision loss and save lives. 
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INTRODUCTION   
 
  Peripheral ulcerative keratitis (PUK) is a rare and severe ocular manifestation 
associated with autoimmune diseases that leads to peripheral corneal thinning and 
potential corneal perforation. PUK has been reported in patients with rheumatoid 
arthritis (RA), polyarteritis nodosa, inflammatory bowel disease, collagen vascular 
diseases such as systemic lupus erythematosus (SLE) and granulomatosis with 
polyangiitis (GPA) (Table 1).1  
 
 




granulomatosis with polyangiitis  
Systemic lupus erythematosus 
Polyarteritis nodosa 
Sjogren Syndrome 
Dermatological disorders Acne rosacea 
Cicatricial pemphigoid 
Stevens-Johnson syndrom 
Inflammatory bowel disease Crohn disease 
Local ocular immunity Mooren ucer 
Table 1: Major Autoimmune Diseases Causing Peripheral Ulcerative Keratitis 
 
The most prevalent forms of autoimmune diseases are RA and SLE. PUK is most 
commonly associated with RA, followed by GPA. The pathophysiology of 
autoimmune diseases remains to be fully uncovered. This group of diseases affect 
most of the organs in the body. The eye, a specialized sensory organ, can be affected 
at any point throughout the course of these diseases. Some of the early signs of 
autoimmune diseases manifested first in the eye, including dry eye disease, 
episcleritis, scleritis, uveitis, and retinitis; therefore, optometrist may be the first 
clinician in the process of a systemic diagnosis. PUK, however, is a late and most 
destructive ocular manifestation of these systemic diseases.1 We present a case 
report of PUK in a patient with a history of rheumatoid arthritis and other 
comorbidities including chronic obstructive lung disease and deep vein thrombosis. 




  A 76-year-old Caucasian male presented with a history red eye OD that started 2 
weeks ago. He saw an outside optometrist and was treated with erythromycin 
ointment for one week. The redness persisted with worsening ocular pain so he 
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went to an urgent care clinic for further evaluation. He was then referred to our eye 
clinic. His medical history consisted of multiple systemic problems including 
chronic obstructive lung disease, hyperlipidemia, deep vein thrombosis, diabetes, 
hypothyroidism, and rheumatoid arthritis. His active medication list included 
Symbicort, tiotropium, atorvastatin, aspirin, levothyroxine, hydroxychloroquine 
and leflunomide. His last comprehensive eye exam two months ago was 
unremarkable. 
 
  The patient complained of moderate ocular pain and was severely photophobic at 
initial presentation. Habitual visual acuity (VA) was 20/80 OD and 20/40-2 OS. 
His refractive error was -1.75-2.75x170 OD, -1.50-1.50x157 OS, and ADD+2.50. 
His pupils were equal and reactive to light without afferent pupillary defect. 
 
  Extraocular movement was full without restriction albeit moderate pain OD. 
Confrontation field was full to finger counting. Cover test was orthophoric. Slit 
lamp evaluation showed severe conjunctival injection and chemosis, a superior 
nasal circular infiltrate and an inferior temporal linear infiltrate across the cornea 
with moderate corneal edema (Fig. 1).  
 
 
    
   Figure 1: Anterior segment photo showed moderate scleritis, superior nasal circular infiltrate, 
   inferior nasal linear infiltrate with corneal thinning OD at initial visit.      





Goldmann applanation tonometry revealed an intraocular pressure of 14 mmHg 
OU. Under the consultation of an ophthalmologist, the patient was diagnosed with 
PUK and moderate scleritis associated with RA and was initially treated with 
Tobradex (tobramycin-dexamethasone) qid OD. Chart review confirmed the 
patient has been treated for RA with hydroxychloroquine and leflunomide for 
several years. His rheumatologist was contacted for co-management, and the 
patient was to return to clinic in two days.  
 
  The patient felt better with Tobradex qid OD over the weekend, but his right eye 
still was viscous and sticky in the morning. His VA remained at 20/80 without 
improvement.  The superior nasal circular infiltrate resolved, and the inferior 
temporal linear infiltrate across the cornea and scleritis were resolving, however 
peripheral corneal thinning persisted. After consultation with his rheumatologist, 
he was put on a pulse treatment of 60 mg prednisone p.o. daily with substitution of 
Tobradex qid for ofloxacin qid, and artificial tears qid.  After two days of oral 
prednisone, the patient felt the same with little improvement, his eye was not sticky 
in the morning and the VA improved to 20/50+2 with less conjunctival injection, 
corneal edema and linear infiltrate. He was recommended to continue the course of 
treatment. 
 
  After a week of oral prednisone, his BCVA improved to 20/40-1, corneal infiltrate 
resolved but the peripheral cornea was thin, so he was referred to a corneal 
specialist for further management while continuing to take prednisone and 
ofloxacin. After a month of oral prednisone and awaiting for a corneal specialist 
consult, the patient felt that his eyes were not experiencing any pain or discomfort 
and doing quite well. His VA was stable at 20/40 OD and the eye has mild 
hyperemia nasally with the persistent linear peripheral corneal thinning (Fig. 2).  
 
         
      Figure 2: Anterior segment photo showed resolving scleritis, resolved superior nasal      
      circular infiltrate and inferior nasal linear infiltrate, but linear corneal thinning persist  
      OD after one month of treatment.     
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Oral prednisone was tapered to 40 mg/d until the next visit in three weeks. At that 
visit, he saw his rheumatologist two days prior and was scheduled to see the corneal 
specialist in two months. His rheumatologist took him off of leflunomide because 
he recently had pneumonia. He continued to take hydroxychloroquine 400 mg/d 
and prednisone 40 mg/d. He developed leg edema and elevated blood sugar over 
the past several weeks while taking high dose of prednisone. His internist was 
informed as a part of the co-management team. His eye felt better and habitual VA 
improved to 20/30-2 OD. Anterior segment optical coherence tomography (OCT) 
of the cornea confirmed persistent peripheral thinning (Fig. 3).  
 
 
 Figure 3: Anterior segment OCT confirmed paracentral corneal thinning to 500um OD. 
 
Patient was to taper prednisone to 30 mg/d for 2 weeks, then 20 mg/d for 2 weeks 
and return to clinic in a month for follow up with dilated fundus exam to monitor 
for hydroxychloroquine maculopathy. Unfortunately, the patient passed away from 
respiratory complications associated with autoimmune disease before he could 
attend his appointment with the corneal specialist.       







  Peripheral ulcerative keratitis is a manifestation of excessive corneal 
inflammatory reaction that leads to corneal tissue damage and subsequent 
curvilinear peripheral stromal thinning. It is often associated autoimmune diseases, 
with RA being the most common underlying cause. The incidence of PUK is 
estimated to be approximately 3 cases per million per year with equal prevalence 
in males and females.1 A recent retrospective review of 18 patients with PUK from 
a multidisciplinary Uveitis Unit from 1996 to 2017 in Barcelona, Spain identified 
8 patients with RA, 2 ANCA-vasculitis, 1 SLE and 1 Takayasu’s arteritis. Three 
cases were idiopathic and the other three were infectious. The median age was 72 
(range 33-85) and women accounted for majority of the cases. Half of the patients 
had associated scleritis and four (33%) patients suffered ocular perforation and 
required surgery.2 This study supports the previous findings that RA accounted 34-
42% of patients with PUK, followed by GPA and SLE.3  
 
  Patients usually present with ocular irritation, pain, redness, photophobia, and 
impaired vision. Important ocular manifestations include scleritis (especially, 
necrotizing scleritis), episcleritis, keratoconjunctivitis sicca, and anterior uveitis. 
The differential diagnosis for PUK is broad as it includes other inflammatory 
condition such as Mooren’s ulcer, Terrien’s marginal degeneration, Pellucid 
marginal degeneration, and other infectious or neoplastic causes.1 Mooren’s ulcer 
also presents with painful peripheral corneal thinning, but adjacent scleritis is not 
seen. Terrien’s marginal degeneration differs from PUK in that it is a painless, 
noninflammatory disease causing peripheral corneal thinning without ulceration. 
Pellucid marginal degeneration causes inferior corneal thinning without 
inflammation and pain.1 A blood work up is essential in identifying the probable 
systemic cause of PUK. Fortunately, the patient was in an integrative health care 
system at a VAMC, his blood work up as well as active medical problems were 
updated regularly and readily available. For clinicians in other settings, laboratory 
tests for potential autoimmune diseases may need to be ordered (Table 2) because 
PUK is unlikely to be idiopathic. Furthermore, 50% of PUK cases are associated 
with collagen vascular disease.1 
 
Table 2 
Laboratory test Indications 
Complete Blood Count (CBC) Hematology 
Complete Metabolic Profile (CMP) Metabolism 
Urinalysis with microscopic analysis 
(UA & micro) 
Kidney elimination 
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Laboratory test Indications 
Erythrocyte Sedimentation Rate (Sed 
Rate) 
Inflammation 
C-Reactive Protein (CRP) Inflammation 
Antinuclear Antibody (ANA) Systemic lupus erythematosus 
Anti-Neutrophil Cytoplasmic Antibody 
(ANCA) 
Granulomatosis with polyangiitis 
Rheumatoid Factor (RF) Rheumatoid arthritis, Sjorgren’s 
syndrome 
Anti-Cyclic Citrullinated Peptide (anti-
CCP) 
Rheumatoid arthritis 
Fluorescent Treponemal Antibody 
(FTA-Abs) 
Syphillis 
Purified Protein Derivative (PPD) Tuberculosis 
Corneal Culture Infection 
Ultrasound of the eye Neoplasm 
Table 2: Recommended laboratory test to identify potential systemic cause of PUK.1 
 
  The pathogeneses of PUK associated with RA are not fully understood but 
cumulative evidence suggests that both T cells and antibodies are involved in the 
manifestation.4 Peripheral cornea is well vascularized with abundant immune cells 
that can be activated abnormally in RA and other autoimmune diseases. The 
deposition of antigen-antibody complexes and subsequent inflammatory reactions 
induces macrophages and keratocytes to elevate the levels of proteolytic enzymes 
such as matrix metalloproteinases and collagenases that degrade corneal collagens 
and extracellular matrices leading to thinning and potential perforation.5   
 
  The goal in the treatment of RA is to control synovitis and prevent joint injury. 
All patients with active RA are treated with disease-modifying antirheumatic drugs 
(DMARDs) to prevent, arrest, or retard joint injury. Methotrexate (MTX), 
hydroxycholorquine (HCQ), sulfasalazine (SSZ) and leflunomide (LEF) are the 
conventional DMARDs often used as initial therapy with a preference for MTX. 
Nonsteroidal anti-inflammatory drugs (NSAIDs, 3200 mg of ibuprofen, 1000 mg 
naproxen, or 20 mg piroxicam per day) and/or glucocorticoids (5 to 10 mg/d) is 
added for initial symptomatic control of inflammation while awaiting the response 
to DMARD therapy.6 Biologic DMARDs including etanercept, adalimumab, 
tofacitinib are alternative medications for patients who are unable or unwilling to 
take traditional DMARDs. For refractory cases that are not responsive to above 
treatments, infliximab or rituximab may be needed.1 The management of acute 
PUK is to calm the inflammation by using topical corticosteroid with an adjunct 





broad-spectrum antibiotic to prevent infection because the cornea is compromised. 
Systemic corticosteroids are considered first-line therapy to control systemic 
inflammation. Topical cyclosporine-A can be considered because it can suppress 
damaging immunological response.7 Anterior segment OCT can be used to monitor 
for progressive or resolving cornea thinning. When corneal perforation occurs, 
surgical procedures involving corneal glue, conjunctival flaps, amniotic membrane 
grafts and penetrating keratoplasty are necessary.8  
 
  Prior to the advent of efficacious DMARDs, the mortality rate of patients with 
RA-associated PUK was up to 50% because it may herald systemic vasculitis.9 
After the advent of DMARDs, the mortality rate of patients with RA-associated 
PUK is expected to be lower but there has not been a more recent study with 
updated estimates. Visual acuity is usually poor for patients with PUK, up to 2/3 of 




   In conclusion, early diagnosis and proper management of PUK in patients with 
autoimmune diseases including RA is vital to preserving sight and saving life. A 
co-management team consisting of internist, rheumatologist, pharmacist and eye 
care providers including corneal specialists are crucial to manage the complexity 
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